# AQST-108 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aqst-108

> AQST-108, sponsored by Aquestive Therapeutics, Inc. (AQST), received a complete response letter from the FDA; the decision is dated January 30, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is AQST-108 FDA approved?

Not as of November 16, 2026. AQST-108, sponsored by Aquestive Therapeutics, Inc. (AQST), received a complete response letter from the FDA; the decision is dated January 30, 2026. SEC Form 10-Q: "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, to fund additional development and commercial activities, and that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt service." [Calendar and source filings](https://sec-api.dev/pdufa/aqst-108)

Source: SEC Form 10-Q, accession 0001398733-26-000074, https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/pdufa/aqst-108#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | AQST-108 |
| Codes | AQST-108 |
| Sponsor | Aquestive Therapeutics, Inc. (AQST) https://sec-api.dev/companies/aqst/catalysts |
| Indications | [alopecia areata](https://sec-api.dev/indications/alopecia-areata) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 26, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-01-13, last confirmed 2025-03-10.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-011465): "Received FDA approval on April 26, 2024*" https://www.sec.gov/Archives/edgar/data/1398733/000162828025011465/corporatepresentationmar.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001229): "Received FDA approval on April 26, 2024" https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/corporatepresentationjan.htm

### Q2 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: alopecia areata.
- First seen 2025-01-13, last confirmed 2025-03-05.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010422): "The Company remains on track to begin its Phase 2a clinical trial of AQST-108 in patients with AA in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001229): "Successfully completed AQST-108 (epinephrine) Topical Gel pre-IND meeting and on track to begin Phase 2a clinical trial in alopecia areata in Q2 2025" https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqstbusinessupdate2025-f.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001229): "The written response received from the FDA was supportive of continued development and Aquestive remains on track to begin its Phase 2a trial in patients with alopecia areata (AA) in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqstbusinessupdate2025-f.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001229): "After completion of pre-IND meeting with the FDA, the Company plans on commencing the Phase 2a study in Q2 2025. 2." https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/corporatepresentationjan.htm

### Q4 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Indication: alopecia areata.
- First seen 2025-08-11, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0001398733-25-000012): "Aquestive continues to work toward its anticipated submission of an Investigational New Drug Application for AQST-108 for the treatment of alopecia areata (AA) to the FDA in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm

### 1H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2. Indication: alopecia areata.
- First seen 2025-05-12, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-024659): "Aquestive plans to initiate its Phase 2a clinical trial of AQST-108, a topical gel formulation for the treatment of alopecia areata (AA), in the first half of 2026, after the launch of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000162828025024659/q12025-ex991earningsrelease.htm

### January 30, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-03-04, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001398733-26-000074): "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, to fund additional development and commercial activities, and that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt service." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm
- SEC Form 10-Q (accession 0001398733-26-000042): "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, to fund additional development and commercial activities, and that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt service." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm
- SEC Form 10-Q (accession 0001398733-26-000030): "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, and to fund additional development and commercial activities that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt service." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000030/aqst-20260331.htm
- SEC Form 10-K (accession 0001398733-26-000018): "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, and to fund additional development and commercial activities that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000041): "In the second quarter of 2026, Aquestive completed the human factors validation study and the pharmacokinetic (PK) study required to address the deficiencies identified in the Complete Response Letter (CRL) issued by the FDA dated January 30, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000016): "Received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/q42025supplementalearnin.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000035): "Excerpts from the clinical pharmacology section from FDA Complete Response Letter received on January 30, 2026. 2." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/hfandclinicalstudystudys.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000035): "Specifically, the Company received a Complete Response Letter (CRL) from the FDA in January 2026 which indicated that, in a previous human factors study, participants had difficulty opening the pouch, tore the film during pouch opening, incorrectly placed the film during administration, chewed the film, and/or removed the film after administration." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/humanfactorspkstudyresul.htm
- SEC Form 10-Q (accession 0001398733-26-000074): "On January 30, 2026, the Company received a CRL that focused on administration and labeling guidance." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm
- SEC Form 10-Q (accession 0001398733-26-000042): "On January 30, 2026, the Company received a CRL that focused on administration and labeling guidance." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm
- SEC Form 10-Q (accession 0001398733-26-000030): "On January 30, 2026, the Company received a CRL that focused on administration and labeling guidance." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000030/aqst-20260331.htm
- SEC Form 10-K (accession 0001398733-26-000018): "On January 30, 2026, the Company received a CRL that focused on administration and labeling guidance." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm

### January 31, 2026: FDA advisory committee meeting

- Status: scheduled. Date confidence: exact.
- First seen 2025-08-15, last confirmed 2025-08-15.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-031374): "Submission Completed NDA Accepted by the FDA Potential Advisory Committee Meeting Q2 2025 Q3 2025 Q4 2025 Q1 2026 PDUFA action date is scheduled for January 31, 2026 Strictly Confidential." https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/ef20053945_ex99-1.htm

### Q2 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-03-04, last confirmed 2026-03-04.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000016): "Building on these results, the Company successfully completed dosing in a second Phase 1 clinical trial in the first quarter of 2026 and the data readout from the study is expected in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm
- SEC Form 10-K (accession 0001398733-26-000018): "Dosing of subjects in a second Phase 1 clinical trial was successfully completed in the first quarter of 2026 and the data readout from the study is expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm

## Same indication

- [HCW9302](https://sec-api.dev/pdufa/hcw9302) (HCWB)

Calendar months: [January 2026](https://sec-api.dev/fda-calendar/2026-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aqst-108.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AQST-108 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aqst-108

```bibtex
@misc{secapidev_pdufa_aqst_108_20261116,
  title        = {AQST-108 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aqst-108}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aqst_108_20261116","title":"AQST-108 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aqst-108","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
